Improving the efficacy of RAAS blockade in patients with chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Renin-angiotensin-aldosterone system (RAAS) blockade is a primary strategy for managing chronic kidney disease (CKD).
• Despite RAAS blockade, many CKD patients experience insufficient proteinuria reduction and continued renal function decline.
• Intensification strategies like dose escalation, multiple RAAS agents, and sodium restriction show short-term benefits.

Purpose of the Study:

• To evaluate the long-term renal and cardiovascular outcomes of different RAAS blockade and dietary sodium intake strategies in CKD patients.
• To compare the efficacy of dual-agent RAAS blockade versus single-agent RAAS blockade combined with dietary sodium restriction.

Main Methods:

• Analysis of large clinical trials and post-hoc analyses of landmark nephrology trials.
• Focus on outcomes related to renal function and cardiovascular events in CKD patients under different treatment regimens.

Main Results:

• Large trials indicate that multiple-drug RAAS blockade does not improve long-term renal or cardiovascular outcomes.
• Post-hoc analyses suggest that reduced dietary sodium intake during single-agent RAAS blockade yields beneficial renal and cardiovascular effects.
• Prospective confirmation of dietary sodium restriction's long-term impact is pending.

Conclusions:

• Current evidence supports combining single-agent RAAS blockade with dietary sodium restriction for CKD management.
• This strategy appears more beneficial for mitigating renal and cardiovascular disease burden than dual-agent RAAS blockade.
• Lifestyle modifications, specifically sodium reduction, are crucial in optimizing renoprotective and cardioprotective interventions for CKD.